Giant Semaglutide Thread (and other GLP-1 / GIP agonists)

[Doodle]

Wanted to create a thread where everyone can post their experiences with different sourced Semaglutide.

Who are you using?
Pharma vs non?
Dosage?
How long have you been taking it?
What are your thoughts?
Have you lost weight?
Side effects?
Oral vs injection?
Tests?

 

[Photon]

In higher doses, mazdutide is extremely effective. Granted that both studies I cite are small. However, they achieved their weight loss with patients on the high doses for extremely short time periods. Ji, et al. (2022). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity - a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine 54, 101691; Bhattachar, et al. (pre-publication, 2025-08-20). Mazdutide reduces body weight in adults with overweight or obesity - A high-dose Phase 1 trial. Diabetes Obesity & Metabolism, doi.org/10.1111/dom.70040.

When looking at studies of mazdutide, it's important to distinguish between studies conducted in China and those in the US. The populations in China tend to have far lower BMIs to begin with. As a result, they are likely to lose less weight.

If i base it off liver fat reduction %, it's slightly weaker than reta on a mg-to-mg basis, at a significantly higher cost.

 

[bananafeet]

If i base it off liver fat reduction %, it's slightly weaker than reta on a mg-to-mg basis, at a significantly higher cost.

It ain't cheap but it works great.

 

[keengkong]

Here is a collection of articles concerning mazdutide:

Mazdutide prescribing instructions - English language summary, Microsoft OneDrive.

Mazdutide prescribing instructions translated into English. This is not easy to read, Microsoft OneDrive.

Mazdutide prescribing directions - in the original Chinese, Microsoft OneDrive .

Anderson (2025). Emerging concepts in obesity management - focus on glucagon receptor agonist combinations. Drugs Context 14, https://www.drugsincontext.com/wp-content/uploads/2025/07/dic.2025-4-8.pdf.

Ayesh, et al. (2024). Letter to the Editor - Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management - Meta-Analysis of Randomized Controlled Trials. Am. J. Therapeutics 31(5), e619-3622, Microsoft OneDrive.

Bailey, et al. (2025). Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides 187, 171380, https://www.sciencedirect.com/science/article/pii/S0196978125000415?via=ihub.

Bhattachar, et al. (pre-publication, 2025-08-20). Mazdutide reduces body weight in adults with overweight or obesity - A high-dose Phase 1 trial. Diabetes Obesity & Metabolism, doi.org/10.1111/dom.70040, Microsoft OneDrive.

Chen, et al. (2021). 682-P - Novel Dual Glucagon and Glucagon-Like Peptide-1 Receptor Agonist LY3305677 Improves Glucose Control, Reduces Body Weight, and Increases Energy Expenditure in Mice, https://diabetesjournals.org/diabet...1/682-P-Novel-Dual-Glucagon-and-Glucagon-Like.

Cheng, et al. (2025). Efficacy and Safety of Dose-Escalated Mazdutide, a GLP-1/GCGR Dual Agonist, in an Adolescent with Obesity, Type 2 Diabetes, and Hyperuricemia - A Case Report. Frontiers Endocrinol. 16, 1654506, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1654506/pdf.

Deng, et al. (2024). Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity - A systematic review and meta-analysis of randomized controlled trials. Endocrine 86(1), 15-27, Microsoft OneDrive.

Dong, et al. (2025). Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction - mechanistic insights from multiomics analysis. EBioMedicine, 117. Obesity Pillars 13, 100162, https://www.thelancet.com/pdfs/journals/ebiom/PIIS2352-3964(25)00235-X.pdf.

Eli Lilly (rev. 2025-09-26). A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder. NCT06817356, ClinicalTrials.gov .

European Assn. for the Study of Diabetes (Sep. 11, 2024). Mazdutide vs dulaglutide in patients with type 2 diabetes (DREAMS-2) - a randomised, open-label, 28-week phase 3 trial. Oral Presentation # LBA 16. Video and Powerpoint Presentation, Media Centre.

Forst, et al. (2024). The role of incretin receptor agonists in the treatment of obesity. Diabetes Obesity Metabolism 26(10), 4178-4196, https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15796.

Globe and Mail (Aug. 30, 2025). Eli Lilly’s Promising Study on Mazdutide for Alcohol Use Disorder - A Financial Perspective, Eli Lilly’s Promising Study on Mazdutide for Alcohol Use Disorder: A Financial Perspective.

Gogineni, et al. (2024). Expert Opin Pharmacother. Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes - where are we now[Q] Expert Opn. Pharmacother. 25(7), 801-818, https://www.tandfonline.com/doi/full/10.1080/14656566.2024.2356254#abstract.

Guo, et al. (2025). Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction - A model-based meta-analysis of placebo-controlled trials. Obesity Pillars 13, 100162, https://www.sciencedirect.com/science/article/pii/S2667368125000063.

Innovent Biologics (Jun. 24, 2024). Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024. Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024.

Innovent Biologics (Sept. 11, 2024). Head-to-head Superiority over Dulaglutide - Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024, Head-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024.

Innovent Biologics (Sept. 14, 2024). Mazdutide Outperforms Dulaglutide in Chinese Type 2 Diabetes - Phase 3 DREAMS-2 Results Presented at EASD 2024, Mazdutide Outperforms Dulaglutide in Chinese Type 2 Diabetes: Phase 3 DREAMS-2 Results Presented at EASD 2024.

Innovent Biologics (May 15 2025) Second Head-to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3), Second Head-to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3).

Innovent Biologics (June 15, 2025). Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China. Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China.

Innovent Biologics (Jun. 24, 2025). Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions, Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions.

Innovent Biologics (Jun. 27, 2025). Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management, Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management.

Innovent Biologics (Sep. 19, 2025). Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes, innovent.

Ji, et al. (2024). 1856-LB - Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1). Diabetes 73 (Supplement_1), https://diabetesjournals.org/diabet...9/1856-LB-Efficacy-and-Safety-of-Mazdutide-in.

Ji, et al. (2024). 1857-LB - Improvement of Liver Steatosis by Mazdutide in Chinese Participants with Overweight or Obesity—An Exploratory Analysis of GLORY-1. Diabetes 73 (Supplement_1), https://diabetesjournals.org/diabet...558/1857-LB-Improvement-of-Liver-Steatosis-by.

Ji, et al. (2023). A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature Comm. 14(1), 8289. https://www.nature.com/articles/s41467-023-44067-4.pdf.

Ji, et al. (2021). IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity - A randomised, placebo-controlled, multiple ascending dose phase 1b study. eClinicalMedicine, 39, 101088, https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00368-0/fulltext.

Ji, et al. (2025). Once-weekly mazdutide in Chinese adults with obesity or overweight. New Engl. J. Med. 392(22), 2215-2225, https://infomed.com.ar/im2025/wp-content/uploads/2025/06/NEJM-Mazdutide.pdf. For the Reader's Digest version of the article, read Innovent Biologics (May 25, 2025) Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM), https://www.prnewswire.com/news-rel...gland-journal-of-medicine-nejm-302464859.html, or Monostra (Jul. 9, 2025). Once-weekly mazdutide tied to significant weight loss in Chinese adults with obesity. Endocrine Today, https://www.healio.com/news/endocri...nt-weight-loss-in-chinese-adults-with-obesity . See also Zhang, et al. (2025). Correspondence. Once-Weekly Mazdutide in Obesity or Overweight. Reply. New England J. Med. 393(10), 1040-1040, https://1drv.ms/b/c/d63cedb6db1eefc3/ET6-mBfWyRFAk82oovnYUlIB42iOVZ69SoMzUAbReOa2fA?e=pZLrDbdoi.org/10.1056/nejmc2509841.

Ji, et al. (2022). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity - a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine 54, 101691, https://www.sciencedirect.com/science/article/pii/S2589537022004217.

Jiang, et al. (2022). A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nature Comm. 13(1), 3613, https://www.sciencedirect.com/science/article/pii/S2589537022004217.

Jiang, et al. (2023). 77-LB - A Novel Glucagon-Like Peptide-1 (GLP-1R) and Glucagon (GCGR) Receptor Dual Agonist, Mazdutide (IBI362), Attenuates Hyperuricemia in Hyperuricemic Rats. Diabetes 72 (Supplement_1), https://diabetesjournals.org/diabet...LB-A-Novel-Glucagon-Like-Peptide-1-GLP-1R-and.

Jiang, et al. (2024). 1866-LB - A Phase 2 Study of Mazdutide 9 mg in Chinese Adults with BMI of 30 kg-2 or more. Diabetes 73 (Supplement_1), https://diabetesjournals.org/diabet.../1866-LB-A-Phase-2-Study-of-Mazdutide-9-mg-in.

Jiang, et al. (2025). A phase 2 study of mazdutide 9 mg in Chinese adults with BMI≥30 kg/m2 [abstract]. Diabetologia 67(1 Suppl) - S351–2, https://diabetesjournals.org/diabet.../1866-LB-A-Phase-2-Study-of-Mazdutide-9-mg-in.

Jinhua & Li (2025). Structural Insights into Multiplexed Pharmacological Actions of Mazdutide At the Glp-1 or Glucagon Receptors, https://dx.doi.org/10.2139/ssrn.5376321.

Kansteiner (Jun. 27, 2025). With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs. Fierce Pharma, https://www.fiercepharma.com/pharma...zMjkwMjAkbzEkZzEkdDE3NjAzMjkxMjAkajU5JGwwJGgw.

Kaufmann & Schlesinger (2025). Could Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Play a Role in Gout Treatment[Q] Pharmaceutics 17(7), 865, https://www.mdpi.com/1999-4923/17/7/865.

Kokkorakis, et al. (2025). Emerging pharmacotherapies for obesity - a systematic review. Pharmacol. Rev. 77(1), 100002, https://1drv.ms/b/c/d63cedb6db1eefc3/EUaRJGVcafJDrsu3psZYorkBSWb-F1GmuSJzWCbHik6HZA?e=zWbXaR.

Kuo, et al. (2025). Semaglutide versus other GLP-1 receptor agonists in patients with MASLD. Hepatol. Comm. 9(7), e0747, https://journals.lww.com/hepcomm/fu..._versus_other_glp_1_receptor_agonists.21.aspx.

Lee, et al. (2025). Glucagon in metabolic disease - a mini-review of emerging multi-organ roles beyond glycemic control. Frontiers Endocrinol. 16, 1645041, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1645041/full.

Liu (2025). Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with-without type 2 diabetes - a systematic review and network meta-analysis. Frontiers Endocrinol. 16, 1513641, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1513641/pdf.

Lubberding, et al. (2024). Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node. Cardiovascular Res. 120(12), 1427-1441, https://pmc.ncbi.nlm.nih.gov/articles/PMC11472427/.

Madsbad & Holst (2025). The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity - a look at phase 2 and 3 pipelines. Expert Opn. Investigational Drugs 34(3), 197-215, https://www.tandfonline.com/doi/pdf/10.1080/13543784.2025.2472408.

Mazdutide - the overlooked middle child, https://1drv.ms/b/c/d63cedb6db1eefc3/EUbz2IpleGlPv4_ohp0dScIBcaYm-ahOYkU-JW7mU5Ofvg?e=3bh21B.

McGlone & Tan (2024). Glucagon-based therapy for people with diabetes and obesity - what is the sweet spot[Q] Peptides 176, 171219, https://www.sciencedirect.com/scien...s=vor&utm_source=wiley&getft_integrator=wiley.

Melson, et al. (2025). What is the pipeline for future medications for obesity[Q] Int'l J. Obesity 49, 433–451, https://www.nature.com/articles/s41366-024-01473-y.

Moiz, et al. (2025). Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes - a systematic review of randomized controlled trials. Annals Internal Med. 178(2), 199-217, https://1drv.ms/b/c/d63cedb6db1eefc3/EVyij7WIMRdOsScPPSVuIUABnT2JFVA6faNS-bbBUxn6bg?e=pdFkU9.

Nalisa, et al. (2024). Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients - a systematic review and meta-analysis of randomized controlled trials. Frontiers Endocrinol. 15, 1309118, https://1drv.ms/b/c/d63cedb6db1eefc3/EdNLrewnNXNPkyds_kItrooBGkcWNZTnfKBDRjfXop7T-A?e=F0WOHU.

Neff (pre-publication, 2025). Shared mechanistic pathways of glucagon signalling - Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions. Diabetes Obesity & Metabolism, https://doi.org/10.1111/dom.70148, https://1drv.ms/b/c/d63cedb6db1eefc3/EQ_h6aDpjnhFpjcWJvfdybgBSmRBURjcrQrO3PSF5vYI2w?e=D4myAC.

PR Newswire, Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions, Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions.

Novikoff & Muller (2023). The molecular pharmacology of glucagon agonists in diabetes and obesity. Peptides 165, 171003, https://www.sciencedirect.com/science/article/pii/S0196978123000657?via=ihub.

PR Newswire (Aug. 21, 2019). Innovent Enters a Licensing Agreement with Lilly to Develop & Commercialize a Novel Diabetes Medicine in China, https://www.prnewswire.com/news-rel...vel-diabetes-medicine-in-china-300905146.html.

Ren, et al. (2025). 775-P - Mazdutide, a Dual GLP-1R/GCGR Agonist, Reduces Hyperuricemia by Modulating Energy and Lipid Metabolism and Inhibiting Hepatic Purine Metabolism. Diabetes 74 (Supplement_1), https://diabetesjournals.org/diabet...-Mazdutide-a-Dual-GLP-1R-GCGR-Agonist-Reduces.

Roy (Jul. 15, 2025). China's rival to Ozempic will now be sold online. Newsbyte, https://www.newsbytesapp.com/news/b...artners-with-jd-health-for-distribution/story.

Silver (Sep. 22, 2025). Innovent's weight-loss drug highlights China challenge for Novo, Lilly. Reuters, https://www.reuters.com/business/he...lights-china-challenge-novo-lilly-2025-09-22/ [Mazdutide is approved for sale in China and appears to be on sale according to advertisements].

Shirley (pre-publication, 2025). Mazdutide - First Approval. Drugs. https://1drv.ms/b/c/d63cedb6db1eefc...kk2https://doi.org/10.1007/s40265-025-02249-y.

Sidrak, et al. (2024). Approved and Emerging Hormone-Based Anti-Obesity Medications - A Review Article. Indian J. Endocrinol. & Metabolism 28(5), 445-460, https://journals.lww.com/indjem/ful...nd_emerging_hormone_based_anti_obesity.3.aspx.

Son, et al. (pre-publication, 2025). Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity. Endocrine Rev., https://1drv.ms/b/c/d63cedb6db1eefc3/ERrlb5vF_IVFv2GDcI8fBYcBdTqoFb2HjNnGrN4USA-F0Q?e=x41Wvc, https://doi.org/10.1210/endrev/bnaf036.

Stachteas, et al. (2025). Efficacy of Dual Glucagon and Glucagon-like Peptide-1 Receptor Agonists Across the Cardiometabolic Continuum - A Review of Current Clinical Evidence. Rev. Cardiovasc. Med. 26(7), 39691, https://pmc.ncbi.nlm.nih.gov/articles/PMC12326405/.

Taylor (May 11, 2023). Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro[Q] Fierce Biotech, https://www.fiercebiotech.com/biote...eight-innovent-study-it-enough-rival-mounjaro.

Wang & Li (2025). 1616-P - Effect of Mazdutide on MASH Fibrosis—Targeting the Liver–Gut Axis and Microbiome. Diabetes 74 (Supplement_1), https://diabetesjournals.org/diabet...8/1616-P-Effect-of-Mazdutide-on-MASH-Fibrosis.

Winther & Holst (2024). Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity. Diabetes, Obesity and Metabolism 26(9), 3501-3512, https://dom-pubs.onlinelibrary.wiley.com/doi/pdf/10.1111/dom.15693.

Wu, et al. (2025). 777-P - The Dual Glucagon and Glucagon-Like Peptide 1 Receptor Agonist Mazdutide Outbalanced Glucagon-Like Peptide 1 Receptor Agonist Semaglutide Monotherapy in Improving Mice Liver Fat Accumulation. Diabetes, 74 (Supplement_1), https://diabetesjournals.org/diabet...P-The-Dual-Glucagon-and-Glucagon-Like-Peptide. https://doi.org/10.2337/db25-777-P.

Xia, et al. (2025). Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet-induced Mouse Model. Radiol. 316(2), e243780, https://dom-pubs.onlinelibrary.wiley.com/doi/pdf/10.1111/dom.15693.

Xie, et al. (2024). Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight - an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism 161, 156038, https://www.metabolismjournal.com/article/S0026-0495(24)00266-X/pdf.

Yang, et al. (2025). Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction - A Systematic Review and Meta-Analysis. J. Diabetes 17(3),e70063, https://onlinelibrary.wiley.com/doi/full/10.1111/1753-0407.70063.

Yao, et al. (2024). Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ 384, e076410, https://www.bmj.com/content/bmj/384/bmj-2023-076410.full.pdf.

Zhang, et al. (2025). Focus on Glucagon-like Peptide-1 Target - Drugs Approved or Designed to Treat Obesity. Int'l J. Molecular Pharmacol. 26(4), 1651, https://www.mdpi.com/1422-0067/26/4/1651.

Zhang, et al. (2024). Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes - a randomized, double-blind, placebo-controlled phase 2 trial. Diabetes Care, 47(1), 160-168, https://diabetesjournals.org/care/a...8/Efficacy-and-Safety-of-Mazdutide-in-Chinese.

Zhang, et al. (2025). Correspondence. Once-Weekly Mazdutide in Obesity or Overweight. Reply. New England J. Med. 393(10), 1040-1040, https://1drv.ms/b/c/d63cedb6db1eefc3/ET6-mBfWyRFAk82oovnYUlIB42iOVZ69SoMzUAbReOa2fA?e=pZLrDbdoi.org/10.1056/nejmc2509841.

Zhang & Li (2025). Structural Insights into Multiplexed Pharmacological Actions of Mazdutide At the Glp-1 or Glucagon Receptors. (2025, pre-publication), https://1drv.ms/b/c/d63cedb6db1eefc3/ERX4rchALitMjCSP9PwgFXQBdly3954OIBixXxUcu5NH4g?e=kYnNml.

Zhu, et al. (2025). 306-OR - Mazdutide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (DREAMS-1). Diabetes 4(Supplement_1),
https://diabetesjournals.org/diabet...306-OR-Mazdutide-vs-Placebo-as-Monotherapy-in.

Names of Phase 3 clinical trials involving mazdutide.

GLORY-1 (NCT05607680) - A Phase 3 clinical study conducted in Chinese adults with overweight of obesity (completed), https://www.nejm.org/doi/full/10.1056/NEJMoa2411528;
GLORY-2 (NCT06164873) - A Phase 3 clinical study conducted in Chinese adults with moderately to severely obesity, estimated completion date 2025-09-19), https://clinicaltrials.gov/study/NCT06164873;
GLORY-3 (NCT06884293) - A Phase 3 clinical study comparing IBI362 [mazdutide] versus semaglutide in Chinese adults with overweight of obesity accompanied metabolic-associated fatty liver disease (MAFLD), estimated completion date 2027-06-30, https://clinicaltrials.gov/study/NCT06884293;
GLORY-OSA (NCT06931028) - A Phase 3 trial in Chinese participants with obstructive sleep apnea (OSA) and obesity, estimated completion date 2027-05-07, https://clinicaltrials.gov/study/NCT06931028;
DREAMS-1 (NCT05628311) - A Phase 3 clinical study conducted in Chinese adults with untreated type 2 diabetes completed), Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions;
DREAMS-2 (NCT05606913) - A Phase 3 clinical study comparing mazdutide versus dulaglutide in Chinese adults with type 2 diabetes who have poor glycemia control with oral medication by (completed), https://finance.yahoo.com/news/innovent-mazdutide-superior-trulicity-phase-103110523.html;
DREAMS-3 (NCT06184568) - A Phase 3 clinical study comparing IBI362 [mazdutide] versus semaglutide in Chinese adults with type 2 diabetes and obesity, estimated completion date 2026-06-30, https://clinicaltrials.gov/study/NCT06184568.

 

[Deadpool99]

Increased my reta dose this week, at 18mg/week now.
That stupid feeling on the skin is back!
Appetite suppression is back too, haven't felt that..in a very long time.

nice to see someone going above 15mg. Did u taper quick from 15 to 18mg, may I ask the timeline? cuz I'd probably be dumb enough to go straight from 15 to 19mg considering how little I feel the appetite.

I'm at 15mg rn for the past 1.5 months, decided to add cagri, 3rd week in and just bumped up to 2mg, will continue with cagri to see if that shit does anything. I get appetite suppression but not as strong, very feint but some studies show non-responders needed upwards to 2.5mg to feel it so I'm hopeful. Sucks not being able to be full on minimal glp1 like many ppl ik.

 

[Photon]

nice to see someone going above 15mg. Did u taper quick from 15 to 18mg, may I ask the timeline? cuz I'd probably be dumb enough to go straight from 15 to 19mg considering how little I feel the appetite.

I'm at 15mg rn for the past 1.5 months, decided to add cagri, 3rd week in and just bumped up to 2mg, will continue with cagri to see if that shit does anything. I get appetite suppression but not as strong, very feint but some studies show non-responders needed upwards to 2.5mg to feel it so I'm hopeful. Sucks not being able to be full on minimal glp1 like many ppl ik.

taper?
no.
im doing 50mg/3 now but SSA vials are usually overdosed by 10%, so it's more like 55/3 a week

 

[dinfar1337]

Increased my reta dose this week, at 18mg/week now.
That stupid feeling on the skin is back!

have you done previous heart scans and are planning to do in the near future?

would love to see if theres even subtle reverseable change with that high reta. or no change or improvements

refering to [GUIDE]: Preventing Cardiovascular & Neurotoxic effects of AAS via Antioxidants

although i have no idea since phase 1 and 2 trials dont contain any scanning/data related to the heart and cv risk beside mentioning the increased heart rate and brushing it off as reta isnt the factor that caused it.

2026-27 triumph outcomes is mainly focused on this and does include cv risk, reduction if there it outweighs the dangers and advanced heart imagining, and long term studies on cv risk. otherwise they wont be able to market it.

i wouldn't recommend going that high with reta until we have that data on it. but might just be a fluke. i really dont think it is since increased rhr is already data on stress on the heart.

 

[Photon]

have you done previous heart scans and are planning to do in the near future?

would love to see if theres even subtle reverseable change with that high reta. or no change or improvements

refering to [GUIDE]: Preventing Cardiovascular & Neurotoxic effects of AAS via Antioxidants

although i have no idea since phase 1 and 2 trials dont contain any scanning/data related to the heart and cv risk beside mentioning the increased heart rate and brushing it off as reta isnt the factor that caused it.

2026-27 triumph outcomes is mainly focused on this and does include cv risk, reduction if there it outweighs the dangers and advanced heart imagining, and long term studies on cv risk. otherwise they wont be able to market it.

i wouldn't recommend going that high with reta until we have that data on it. but might just be a fluke. i really dont think it is since increased rhr is already data on stress on the heart.

I do echo and ekg, no lvh so far.

 

[dinfar1337]

I do echo and ekg, no lvh so far.

thanks

sorry for saying this. in 10 years if it turns out its bad long term, i hope you guys blasting 18mg abusing gcgr effects will go first

instead of little me blasting 1mg a week!

 

[Deadpool99]

taper?
no.
im doing 50mg/3 now but SSA vials are usually overdosed by 10%, so it's more like 55/3 a week

I meant like u clearly had to use lower dose of reta then decided to go to 18mg, I was asking how big of a jump between dosages did u do.

I think my biggest jump was 9mg to 12mg, had too strong of suppression cuz I got cocky then lowered to 11mg and went back to 12 a week later.

Anyways that was my question, was just curious if ur making big jumps or slowly went up.

I was supposed to 60mg vials of SSA but order never shipped, now I'm stuck with 15mg vials

 

[dinfar1337]

taper

titrate up my friend.

taper is not good. its winter and we are blasting up not down

 

[Deadpool99]

titrate up my friend.

taper is not good. its winter and we are blasting up not down

Oh my bad. Some idiots kept saying taper and now I say it too. Ffs I don’t even realize it. Thanks for pointing it out. I usually get pissed when ppl do that.

I never used the word taper until I started reading 18yr old threads.

 

[dinfar1337]

Some idiots kept saying taper

well you can say them both. i just prefer the other because there is tit in the word.

 

[Deadpool99]

well you can say them both. i just prefer the other because there is tit in the word.

Technically taper means decreasing gradually, titrating means adjusting the dose (either up or down).

So in both cases u were right. But the word tit is also a bonus.

 

[Photon]

I meant like u clearly had to use lower dose of reta then decided to go to 18mg, I was asking how big of a jump between dosages did u do.

I think my biggest jump was 9mg to 12mg, had too strong of suppression cuz I got cocky then lowered to 11mg and went back to 12 a week later.

Anyways that was my question, was just curious if ur making big jumps or slowly went up.

I was supposed to 60mg vials of SSA but order never shipped, now I'm stuck with 15mg vials

I think clinical trials used 2 4 8 12, with escalation every 4wks.
I don't quite remember.

For me i simply went up each time i had zero sides.
It was much slower than what clinical trials used for sure.

 

[Deadpool99]

I think clinical trials used 2 4 8 12, with escalation every 4wks.
I don't quite remember.

For me i simply went up each time i had zero sides.
It was much slower than what clinical trials used for sure.

I rly wish I can swap my R15 kits with someone to get some higher one. The sad part is I’m stocked until august 2026 with reta. So I guess I’ll have to roll with what I have.

Bought a R30 kit, got 2 R15 instead. One of them had issues so I got sent an extra R30. I got an infinite supply. Unless I go megadose 18mg.

 

[Photon]

I rly wish I can swap my R15 kits with someone to get some higher one. The sad part is I’m stocked until august 2026 with reta. So I guess I’ll have to roll with what I have.

Bought a R30 kit, got 2 R15 instead. One of them had issues so I got sent an extra R30. I got an infinite supply. Unless I go megadose 18mg.

Mix them.
R15 is like 18mg?

(18x2)/3=12mg a week i guess

 

[Deadpool99]

Increased my reta dose this week, at 18mg/week now.
That stupid feeling on the skin is back!
Appetite suppression is back too, haven't felt that..in a very long time.

Honestly I am interested in the literature if the effects of reta plateau after a certain dose. Cuz I doubt the supression stength as you go higher higher in doses is linear.

My guess is that it is probably less effective per mg in the higher ranges but will never know until I try.

 

[Deadpool99]

Mix them.
R15 is like 18mg?

(18x2)/3=12mg a week i guess

I actually never mixed vials ever, except when I had GHK-CU 100mg vials, def had to get a 10ml vial to dilute the fuck out of it.

 

[Photon]

I actually never mixed vials ever, except when I had GHK-CU 100mg vials, def had to get a 10ml vial to dilute the fuck out of it.

I mix GHK with GLUT
I recon it with glut instead of bac lol

 

[keengkong]

Honestly I am interested in the literature if the effects of reta plateau after a certain dose. Cuz I doubt the supression stength as you go higher higher in doses is linear.

My guess is that it is probably less effective per mg in the higher ranges but will never know until I try.

Tirz 10 and 15 mg result in more weight loss than tirz 5 but you get more bang for the buck (but less total weight loss) using tirz 5.